Eli Lilly Options Traders Put 61% of Premium Into Calls
61% of LLY options premium went to calls on Nov 10 as the stock holds near its $1,453 52-week high, but dark pool volume and a 2-of-5 pattern confidence score temper the bull flag case.
Topic
Eli Lilly
Topic
Eli Lilly
Retatrutide Cut Knee Pain by Half in 63% to 70% of Patients
Northwestern University's Eli Lilly-funded phase 3 trials found 63% to 70% of participants on higher retatrutide doses halved kne…
Foundayo cut sleep apnea events by 21.1 an hour in late-stage trial
Eli Lilly’s Foundayo cut apnea events by 21.1 per hour at 52 weeks in a late-stage trial; Lilly plans a year-end U.S. filing for…
Hims & Hers Stock Jumps 4.7% on Eli Lilly GLP-1 Deal
Hims & Hers will sell Eli Lilly's Zepbound and Foundayo directly, dropping compounding. Shares rose 4.7% Friday but remain down 2…
Eli Lilly Raises 2026 Revenue Outlook to $91–92 Billion
Lilly raised 2026 revenue guidance to $91–92 billion after Q3 EPS of $7.48 beat estimates of $6.26, as Mounjaro sales jumped 65%…
AbbVie, Eli Lilly and Gilead Hit Record Highs as Tech Selloff Reshuffles Money
AbbVie, Eli Lilly and Gilead Sciences shares trade at or near record highs as the tech selloff pushes investors toward pharma as…
Novo's Wegovy Pill Delivers Further Weight Loss for Injection Switchers
Novo says patients switching from Wegovy or Zepbound injections to its new pill lost another 8.8 pounds on average in three month…
Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but…
Johnson & Johnson Returns 58% on Slower Growth Than Eli Lilly
JNJ returned 58% in twelve months, beating Eli Lilly's 54% despite growing revenue at 8.1% versus Lilly's 49.6%. The rally is a b…
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…
Eli Lilly Says One-Third of New GLP-1 Pill Patients Choose Foundayo
One-third of new GLP-1 pill patients pick Foundayo, CEO Dave Ricks says, as Lilly breaks ground on a $6.5 billion Houston plant d…